Hansa Biopharma

Hansa Biopharma is a Nasdaq Stockholm-listed company (HNSA) focused on developing and commercializing first-in-class immunomodulatory therapies for rare immunological conditions. Its core achievement is the development and commercialization of imlifidase, a first-in-class IgG-cleaving enzyme approved in the EU for desensitization in kidney transplantation. The company's strategy leverages its unique enzyme technology platform to expand into acute autoimmune diseases and desensitization for advanced therapies, aiming to transform care in areas of critical unmet medical need.

Proprietary antibody-cleaving enzyme technology that rapidly and specifically inactivates IgG antibodies. The platform includes a first-generation molecule (imlifidase) for single-dose use and a next-generation candidate (HNSA-5487) designed for potential repeat dosing.

Hansa faces competition from established, non-specific desensitization regimens (plasmapheresis/IVIg) in transplantation and standard care in autoimmune diseases. Its primary competitive advantage is the unique speed and specificity of its enzyme platform. In the emerging gene therapy enabling space, it is a first-mover against alternative approaches like immunosuppression or engineered viral capsids.